| Year |
Citation |
Score |
| 2021 |
Desnoyers A, Amir E, Tannock IF. Adjuvant Zoledronate Therapy for Women With Breast Cancer-Effective Treatment or Fool's Gold? Jama Oncology. PMID 34165515 DOI: 10.1001/jamaoncol.2021.1516 |
0.406 |
|
| 2020 |
Templeton AJ, Amir E, Tannock IF. Informative censoring - a neglected cause of bias in oncology trials. Nature Reviews. Clinical Oncology. PMID 32273582 DOI: 10.1038/S41571-020-0368-0 |
0.408 |
|
| 2019 |
Rodríguez-Fernández IA, Rodríguez-Romo L, Hernandez-Barajas D, Gonzalez-Conchas GA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE. Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis. European Urology Oncology. 2: 448-455. PMID 31277782 DOI: 10.1016/J.Euo.2018.10.003 |
0.458 |
|
| 2018 |
Robbrecht DG, Soest RJv, Tannock IF, Oudard S, Tombal B, Eisenberger M, Mercier F, Wit Rd. Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy284.022 |
0.363 |
|
| 2017 |
Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE. Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. Cancer Treatment Reviews. 62: 1-8. PMID 29126017 DOI: 10.1016/J.Ctrv.2017.10.008 |
0.365 |
|
| 2017 |
Winocur G, Berman H, Nguyen M, Binns MA, Henkelman M, van Eede M, Piquette-Miller M, Sekeres MJ, Wojtowicz JM, Yu J, Zhang H, Tannock IF. Neurobiological Mechanisms of Chemotherapy-induced Cognitive Impairment in a Transgenic Model of Breast Cancer. Neuroscience. PMID 29113931 DOI: 10.1016/J.Neuroscience.2017.10.048 |
0.318 |
|
| 2017 |
Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, ... ... Tannock I, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology. PMID 28655541 DOI: 10.1016/J.Eururo.2017.06.002 |
0.366 |
|
| 2017 |
Del Paggio JC, Sullivan R, Schrag D, Hopman WM, Azariah B, Pramesh CS, Tannock IF, Booth CM. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. The Lancet. Oncology. PMID 28583794 DOI: 10.1016/S1470-2045(17)30415-1 |
0.349 |
|
| 2016 |
Tannock IF, Amir E, Booth CM, Niraula S, Ocana A, Seruga B, Templeton AJ, Vera-Badillo F. Relevance of randomised controlled trials in oncology. The Lancet. Oncology. 17: e560-e567. PMID 27924754 DOI: 10.1016/S1470-2045(16)30572-1 |
0.426 |
|
| 2016 |
Alibhai SM, Timilshina N, Duff-Canning S, Breunis H, Tannock IF, Naglie G, Fleshner NE, Krahn MD, Warde P, Marzouk S, Tomlinson GA. Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. Cancer. PMID 27583806 DOI: 10.1002/Cncr.30320 |
0.327 |
|
| 2016 |
Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SM, Chan AW, Ocana A, Templeton AJ, Seruga B, Amir E, Tannock IF. Honorary and ghost authorship in reports of randomised clinical trials in oncology. European Journal of Cancer (Oxford, England : 1990). 66: 1-8. PMID 27500368 DOI: 10.1016/J.Ejca.2016.06.023 |
0.384 |
|
| 2016 |
Seruga B, Templeton AJ, Badillo FE, Ocana A, Amir E, Tannock IF. Under-reporting of harm in clinical trials. The Lancet. Oncology. 17: e209-19. PMID 27301048 DOI: 10.1016/S1470-2045(16)00152-2 |
0.43 |
|
| 2016 |
Zhang S, Liang F, Li W, Tannock I. Comparison of Eligibility Criteria Between Protocols, Registries, and Publications of Cancer Clinical Trials. Journal of the National Cancer Institute. 108. PMID 27226519 DOI: 10.1093/Jnci/Djw129 |
0.322 |
|
| 2016 |
Ocana A, Amir E, Tannock IF. Toward Value-Based Pricing to Boost Cancer Research and Innovation. Cancer Research. 76: 3127-9. PMID 27197164 DOI: 10.1158/0008-5472.Can-15-3179 |
0.473 |
|
| 2016 |
Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SM, Chan AW, Ocana A, Seruga B, Templeton AJ, Amir E, Tannock IF. Bias in reporting of randomised clinical trials in oncology. European Journal of Cancer (Oxford, England : 1990). 61: 29-35. PMID 27151552 DOI: 10.1016/J.Ejca.2016.03.066 |
0.434 |
|
| 2016 |
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, ... ... Tannock IF, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27141017 DOI: 10.1093/Annonc/Mdw180 |
0.349 |
|
| 2016 |
Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, ... ... Tannock IF, et al. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26951312 DOI: 10.1200/Jco.2015.65.7270 |
0.384 |
|
| 2016 |
Hansen A, Tannock I, Templeton A, Prawira A, Knox J, Vera-Badillo F, Chen E, Zavitz M, Wang L, Evans A, Tan Q, Wouters B, Sridhar S, Joshua A. Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): A phase II trial in men with metastatic castrate resistant prostate cancer (mCRPC) Annals of Oncology. 27: vi249. DOI: 10.1093/Annonc/Mdw372.20 |
0.357 |
|
| 2015 |
Seruga B, Ocana A, Amir E, Tannock IF. Failures in Phase III: Causes and Consequences. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4552-60. PMID 26473191 DOI: 10.1158/1078-0432.Ccr-15-0124 |
0.445 |
|
| 2015 |
Ocana A, Vera-Badillo F, Templeton A, Tannock I, Amir E. Response. Journal of the National Cancer Institute. 107. PMID 26283612 DOI: 10.1093/jnci/djv244 |
0.303 |
|
| 2015 |
Tan Q, Saggar JK, Yu M, Wang M, Tannock IF. Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them. Cancer Journal (Sudbury, Mass.). 21: 254-62. PMID 26222076 DOI: 10.1097/Ppo.0000000000000131 |
0.767 |
|
| 2015 |
Vera-Badillo FE, Chang MC, Kuruzar G, Ocana A, Templeton AJ, Seruga B, Goldstein R, Bedard PL, Tannock IF, Amir E. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. Journal of Clinical Pathology. PMID 26076967 DOI: 10.1136/Jclinpath-2015-203012 |
0.388 |
|
| 2015 |
Stapleton S, Milosevic M, Tannock IF, Allen C, Jaffray DA. The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation. Journal of Controlled Release : Official Journal of the Controlled Release Society. 211: 163-170. PMID 26070245 DOI: 10.1016/J.Jconrel.2015.06.008 |
0.302 |
|
| 2015 |
Templeton AJ, Ace O, Amir E, Vera-Badillo F, Ocana A, Pond GR, Tannock IF. Influence of censoring on conclusions of trials for women with metastatic breast cancer. European Journal of Cancer (Oxford, England : 1990). 51: 721-4. PMID 25728257 DOI: 10.1016/J.Ejca.2014.12.016 |
0.467 |
|
| 2015 |
Saggar JK, Tannock IF. Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation-An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2107-14. PMID 25677696 DOI: 10.1158/1078-0432.Ccr-14-2298 |
0.766 |
|
| 2015 |
Leveridge MJ, Siemens DR, Mackillop WJ, Peng Y, Tannock IF, Berman DM, Booth CM. Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study. Urology. 85: 791-8. PMID 25661830 DOI: 10.1016/J.Urology.2014.12.027 |
0.343 |
|
| 2015 |
Tan Q, Joshua AM, Saggar JK, Yu M, Wang M, Kanga N, Zhang JY, Chen X, Wouters BG, Tannock IF. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. British Journal of Cancer. 112: 832-40. PMID 25647012 DOI: 10.1038/bjc.2015.17 |
0.745 |
|
| 2015 |
van Soest RJ, Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E, Tombal B, Rosenthal M, Eisenberger MA, Tannock IF, de Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 743-9. PMID 25515657 DOI: 10.1093/Annonc/Mdu569 |
0.492 |
|
| 2015 |
Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, Knox JJ, Tannock IF, Escudier B, Amir E. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. European Urology. 67: 740-9. PMID 24882670 DOI: 10.1016/J.Eururo.2014.05.010 |
0.405 |
|
| 2015 |
Sonpavde G, Pond GR, Templeton AJ, Petrylak DP, Tombal BF, Rosenthal M, Tannock I. Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 33: 186-186. DOI: 10.1200/Jco.2015.33.7_Suppl.186 |
0.342 |
|
| 2015 |
Tan Q, Joshua AM, Saggar JK, Yu M, Wang M, Wouters B, Tannock IF. Abstract 395: Effect of pantoprazole to enhance activity of docetaxel against human tumor xenografts by inhibiting autophagy Cancer Research. 75: 395-395. DOI: 10.1158/1538-7445.Am2015-395 |
0.782 |
|
| 2015 |
Vera Badillo F, Gonzalez-Guerrero J, Gonzalez-Conchas G, Rodriguez-Fernandez I, Verdines-Perez A, Templeton A, Ocana A, Seruga B, Tannock I, Amir E. 1973 Epidermal growth factor receptor (EGFR) over-expression and outcomes in early breast cancer: A systematic review and meta-analysis European Journal of Cancer. 51: S324-S325. DOI: 10.1016/S0959-8049(16)30921-2 |
0.452 |
|
| 2015 |
Guerra R, Toloi D, Tibau A, Ocana A, Seruga B, Vera-Badillo F, Amir E, Tannock I, Templeton A. 1229 Industry-Sponsored Posters at Major Oncology Conferences: Science or Marketing? European Journal of Cancer. 51: S183. DOI: 10.1016/S0959-8049(16)30533-0 |
0.391 |
|
| 2014 |
Boutron I, Altman DG, Hopewell S, Vera-Badillo F, Tannock I, Ravaud P. Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 4120-6. PMID 25403215 DOI: 10.1200/Jco.2014.56.7503 |
0.317 |
|
| 2014 |
Niraula S, Amir E, Vera-Badillo F, Seruga B, Ocana A, Tannock IF. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3634-42. PMID 25267757 DOI: 10.1200/Jco.2014.55.8437 |
0.457 |
|
| 2014 |
Brana I, Ocana A, Chen EX, Razak AR, Haines C, Lee C, Douglas S, Wang L, Siu LL, Tannock IF, Bedard PL. A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Investigational New Drugs. 32: 1269-77. PMID 25213162 DOI: 10.1007/S10637-014-0159-5 |
0.379 |
|
| 2014 |
Leibowitz-Amit R, Alimohamed N, Vera-Badillo FE, Seah JA, Templeton AJ, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone. The Prostate. 74: 1462-4. PMID 25111736 DOI: 10.1002/Pros.22861 |
0.362 |
|
| 2014 |
Vera-Badillo FE, Ocana A, Templeton AJ, Tibau A, Amir E, Tannock IF. Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3197. PMID 25092777 DOI: 10.1200/Jco.2014.56.2447 |
0.327 |
|
| 2014 |
Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo FE, Attard G, de Bono JS, Tannock IF, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 120: 3346-52. PMID 24995769 DOI: 10.1002/Cncr.28890 |
0.517 |
|
| 2014 |
Vera-Badillo FE, Napoleone M, Ocana A, Templeton AJ, Seruga B, Al-Mubarak M, AlHashem H, Tannock IF, Amir E. Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment. 146: 235-44. PMID 24928527 DOI: 10.1200/Jco.2014.32.15_Suppl.546 |
0.494 |
|
| 2014 |
Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Journal of the National Cancer Institute. 106: dju124. PMID 24875653 DOI: 10.1093/Jnci/Dju124 |
0.428 |
|
| 2014 |
Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocaña A, Tannock IF, Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1204-12. PMID 24793958 DOI: 10.1158/1055-9965.Epi-14-0146 |
0.478 |
|
| 2014 |
Booth CM, Siemens DR, Li G, Peng Y, Tannock IF, Kong W, Berman DM, Mackillop WJ. Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer. 120: 1630-8. PMID 24733278 DOI: 10.1002/Cncr.28510 |
0.352 |
|
| 2014 |
Bernstein LJ, Catton PA, Tannock IF. Intra-individual variability in women with breast cancer. Journal of the International Neuropsychological Society : Jins. 20: 380-90. PMID 24621519 DOI: 10.1017/S1355617714000125 |
0.309 |
|
| 2014 |
Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, De Wit R, Eisenberger MA, Tannock IF. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. Journal of Geriatric Oncology. 5: 119-26. PMID 24495703 DOI: 10.1016/J.Jgo.2013.12.001 |
0.518 |
|
| 2014 |
Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D, Vera-Badillo F, Seah JA, Attard G, Knox JJ, Sridhar SS, Tannock IF, de Bono JS, Joshua AM. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 657-62. PMID 24458472 DOI: 10.1093/Annonc/Mdt581 |
0.377 |
|
| 2014 |
Saggar JK, Tannock IF. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy. International Journal of Cancer. 134: 2726-34. PMID 24338277 DOI: 10.1002/Ijc.28595 |
0.77 |
|
| 2014 |
Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. Journal of the National Cancer Institute. 106: djt319. PMID 24273215 DOI: 10.1093/Jnci/Djt319 |
0.474 |
|
| 2014 |
Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. European Urology. 65: 3-6. PMID 24120464 DOI: 10.1016/J.Eururo.2013.09.024 |
0.308 |
|
| 2014 |
van Soest RJ, de Morrée ES, Shen L, Tannock IF, Eisenberger MA, de Wit R. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study. European Urology. 66: 330-6. PMID 23957945 DOI: 10.1016/J.Eururo.2013.08.007 |
0.384 |
|
| 2014 |
Templeton AJ, Omlin AG, Pezaro CJ, Kheoh TS, Leibowitz-Amit R, Vera-Badillo FE, Tannock I, Attard G, Amir E, De Bono JS. A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy. Journal of Clinical Oncology. 32: 70-70. DOI: 10.1200/Jco.2014.32.4_Suppl.70 |
0.489 |
|
| 2014 |
Leibowitz-Amit R, Atenafu EG, Seah J, Templeton AJ, Vera-Badillo FE, Solow HL, Knox JJ, Sridhar SS, Tannock I, Joshua AM. Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience. Journal of Clinical Oncology. 32: 61-61. DOI: 10.1200/Jco.2014.32.4_Suppl.61 |
0.391 |
|
| 2014 |
Vera-Badillo FE, Templeton A, Ocana A, deGouveia P, Aneja P, Knox JJ, Tannock I, Duran I, Escudier BJ, Amir E. Response to systemic therapy in non-clear cell renal cell carcinomas: A systematic review and meta-analysis. Journal of Clinical Oncology. 32: 425-425. DOI: 10.1200/Jco.2014.32.4_Suppl.425 |
0.495 |
|
| 2014 |
Vera-Badillo FE, Leibowitz-Amit R, Templeton A, Seah J, Sridhar SS, Knox JJ, Tannock I, Joshua AM. Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience. Journal of Clinical Oncology. 32: 159-159. DOI: 10.1200/Jco.2014.32.4_Suppl.159 |
0.367 |
|
| 2014 |
Niraula S, Amir E, Vera Badillo FE, Seruga B, Ocana A, Tannock I. Absolute risk and cost of management of toxicities of newly approved anticancer drugs: A meta-analysis. Journal of Clinical Oncology. 32: e17556-e17556. DOI: 10.1200/Jco.2014.32.15_Suppl.E17556 |
0.382 |
|
| 2014 |
Vera-Badillo FE, Chang M, Kuruzar G, Ocana A, Templeton AJ, Seruga B, Al-Mubarak M, Goldstein R, Bedard PL, Tannock I, Amir E. Association between androgen receptor (AR) expression, Ki-67, and the 21-gene recurrence score in early breast cancer. Journal of Clinical Oncology. 32: 547-547. DOI: 10.1200/Jco.2014.32.15_Suppl.547 |
0.38 |
|
| 2014 |
Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E, Tombal BF, Rosenthal M, Tannock I. Prognostic role of derived neutrophil to lymphocyte ratio (dNLR) in men with metastatic castration resistant prostate cancer (mCRPC) treated in a phase 3 trial (VENICE). Journal of Clinical Oncology. 32: 5047-5047. DOI: 10.1200/Jco.2014.32.15_Suppl.5047 |
0.489 |
|
| 2014 |
Niraula S, Amir E, Seruga B, Vera-Badillo F, Ocana A, Tannock IF. 1386O_Prrisk Of Incremental Toxicities And Associated Costs Of New Anticancer Drugs: A Meta-Analysis Annals of Oncology. 25. DOI: 10.1093/Annonc/Mdu438.55 |
0.518 |
|
| 2013 |
de Morrée E, Shen L, Tannock I, Eisenberger MA, De Wit R. The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 44. PMID 28137000 DOI: 10.1200/Jco.2013.31.6_Suppl.44 |
0.346 |
|
| 2013 |
Wang L, Vera-Badillo F, Attalla M, De Gouveia P, Leibowitz-Amit R, Knox JJ, Moore MJ, Sridhar SS, Joshua AM, Tannock I. From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 125. PMID 28136799 DOI: 10.1200/Jco.2013.31.6_Suppl.125 |
0.373 |
|
| 2013 |
Manji A, Brana I, Amir E, Tomlinson G, Tannock IF, Bedard PL, Oza A, Siu LL, Razak AR. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4260-7. PMID 24127441 DOI: 10.1200/Jco.2012.47.4957 |
0.518 |
|
| 2013 |
Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P, Leibowitz-Amit R, Knox JJ, Moore M, Sridhar SS, Joshua AM, Pond GR, Amir E, Tannock IF. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 2972-7. PMID 24126362 DOI: 10.1093/Annonc/Mdt397 |
0.518 |
|
| 2013 |
Ocana A, Amir E, Vera-Badillo F, Seruga B, Tannock IF. Phase III trials of targeted anticancer therapies: redesigning the concept. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4931-40. PMID 23881926 DOI: 10.1158/1078-0432.Ccr-13-1222 |
0.433 |
|
| 2013 |
Fung AS, Yu M, Ye QJ, Tannock IF. Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor. Cancer Chemotherapy and Pharmacology. 72: 585-95. PMID 23851981 DOI: 10.1007/S00280-013-2229-3 |
0.374 |
|
| 2013 |
Saggar JK, Yu M, Tan Q, Tannock IF. The tumor microenvironment and strategies to improve drug distribution. Frontiers in Oncology. 3: 154. PMID 23772420 DOI: 10.3389/Fonc.2013.00154 |
0.761 |
|
| 2013 |
Niraula S, Pond G, de Wit R, Eisenberger M, Tannock IF, Joshua AM. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 7: E74-81. PMID 23671512 DOI: 10.1200/Jco.2010.28.15_Suppl.4686 |
0.371 |
|
| 2013 |
Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2029-36. PMID 23630216 DOI: 10.1200/Jco.2012.46.5492 |
0.371 |
|
| 2013 |
Caldas C, Tannock IF. Breast cancer: Tamoxifen--when more might be better. Nature Reviews. Clinical Oncology. 10: 125-6. PMID 23380999 DOI: 10.1038/Nrclinonc.2013.17 |
0.33 |
|
| 2013 |
Saggar JK, Fung AS, Patel KJ, Tannock IF. Use of molecular biomarkers to quantify the spatial distribution of effects of anticancer drugs in solid tumors. Molecular Cancer Therapeutics. 12: 542-52. PMID 23348047 DOI: 10.1158/1535-7163.Mct-12-0967 |
0.752 |
|
| 2013 |
Vera-Badillo FE, Shapiro R, Ocana A, Amir E, Tannock IF. Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1238-44. PMID 23303339 DOI: 10.1093/Annonc/Mds636 |
0.52 |
|
| 2013 |
Yu M, Ocana A, Tannock IF. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Reviews. 32: 211-27. PMID 23093326 DOI: 10.1007/S10555-012-9402-8 |
0.343 |
|
| 2013 |
Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. American Journal of Clinical Oncology. 36: 436-42. PMID 22781385 DOI: 10.1097/Coc.0B013E3182568F7A |
0.478 |
|
| 2013 |
Manokumar T, Aziz S, Rizvi F, Breunis H, Joshua AM, Tannock I, Alibhai SM. A prospective study examining PROs and other geriatric outcomes in older adults with prostate cancer undergoing chemotherapy. Journal of Clinical Oncology. 31: 9555-9555. DOI: 10.1200/Jco.2013.31.15_Suppl.9555 |
0.385 |
|
| 2013 |
Leibowitz-Amit R, Templeton AJ, Atenafu EG, Vera-Badillo FE, Chllamma M, Solow HL, Knox JJ, Tannock I, Sridhar SS, Joshua AM. Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC). Journal of Clinical Oncology. 31: 5058-5058. DOI: 10.1200/Jco.2013.31.15_Suppl.5058 |
0.341 |
|
| 2013 |
Tannock I, Fizazi K, Ivanov S, Thellenberg-Karlsson C, Flechon A, Skoneczna IA, Orlandi FJ, Gravis G, Matveev V, Bavbek SE, Gil T, Viana LS, Aren O, Karyakin O, Elliott T, et al. Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 31: 5002-5002. DOI: 10.1200/Jco.2013.31.15_Suppl.5002 |
0.36 |
|
| 2013 |
Bedard PL, Oza AM, Tsao M, Leighl NB, Shepherd FA, Chen EX, Tannock I, Krzyzanowska MK, Dhani NC, Clarke B, Berman HK, Serra S, Craddock KJ, Chadwick D, Zhang T, et al. Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). Journal of Clinical Oncology. 31: 11002-11002. DOI: 10.1200/Jco.2013.31.15_Suppl.11002 |
0.341 |
|
| 2013 |
Tan Q, Joshua A, Saggar J, Yu M, Lee CM, Koritzinsky M, Wouters BR, Tannock IF. Abstract 3829A: Pantoprazole enhances the activity of chemotherapy for solid tumors by inhibition of autophagy. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-3829A |
0.783 |
|
| 2013 |
Saggar JK, Tannock IF. Abstract 3801A: Reoxygenation and repopulation of hypoxic cells in a solid tumor after chemotherapy: a cause of treatment failure. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-3801A |
0.379 |
|
| 2013 |
Alibhai S, Manokumar T, Aziz S, Rizvi F, Breunis H, Gulamhusein H, Timilshina N, Tannock I, Joshua A. Does the hurria/CARG tool or VES-13 predict grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer? Journal of Geriatric Oncology. 4: S37. DOI: 10.1016/J.Jgo.2013.09.031 |
0.365 |
|
| 2012 |
Alibhai SM, Breunis H, Timilshina N, Tomlinson GA, Duff Canning S, Fleshner NE, Krahn M, Tannock I, Warde PR, Naglie G. Impact of 36 months of androgen-deprivation therapy (ADT) on physical function and quality of life (QOL) in men with nonmetastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 16. PMID 27967832 DOI: 10.1200/Jco.2012.30.5_Suppl.16 |
0.308 |
|
| 2012 |
Vardy J, Pond G, Dodd A, Warr D, Seruga B, Clemons M, Bordeleau L, Goodwin P, Tannock IF. A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment. 136: 143-51. PMID 22956006 DOI: 10.1007/S10549-012-2205-3 |
0.361 |
|
| 2012 |
Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, Amir E. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3012-9. PMID 22802313 DOI: 10.1200/Jco.2011.40.3824 |
0.51 |
|
| 2012 |
Seruga B, Pond GR, Hertz PC, Amir E, Ocana A, Tannock IF. Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2977-82. PMID 22734009 DOI: 10.1093/Annonc/Mds174 |
0.48 |
|
| 2012 |
Grantab RH, Tannock IF. Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib. Bmc Cancer. 12: 214. PMID 22672469 DOI: 10.1186/1471-2407-12-214 |
0.327 |
|
| 2012 |
Fung AS, Jonkman J, Tannock IF. Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel. Neoplasia (New York, N.Y.). 14: 324-34. PMID 22577347 DOI: 10.1593/Neo.12346 |
0.356 |
|
| 2012 |
Ocana A, Amir E, Yeung C, Seruga B, Tannock IF. How valid are claims for synergy in published clinical studies? Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2161-6. PMID 22314859 DOI: 10.1093/Annonc/Mdr608 |
0.47 |
|
| 2012 |
Kim S, Tannock I, Sridhar S, Seki J, Bordeleau L. Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 18: 311-5. PMID 22217649 DOI: 10.1177/1078155211429384 |
0.366 |
|
| 2012 |
Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer Journal of Clinical Oncology. 30: 587-592. PMID 22124102 DOI: 10.1200/Jco.2010.33.5232 |
0.515 |
|
| 2012 |
Amir E, Seruga B, Kwong R, Tannock IF, Ocaña A. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? European Journal of Cancer (Oxford, England : 1990). 48: 385-8. PMID 22115991 DOI: 10.1016/J.Ejca.2011.10.028 |
0.544 |
|
| 2012 |
Kim S, Bordeleau L, Tannock IF, Rotstein C. A fatal case of Pneumocystis jirovecii pneumonia in a breast cancer patient receiving weekly paclitaxel and trastuzumab. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 18: 293-5. PMID 21911478 DOI: 10.1177/1078155211412991 |
0.336 |
|
| 2012 |
Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold L, Berry WR, de Wit R, Eisenberger MA, Tannock IF, Sonpavde G. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. European Urology. 61: 363-9. PMID 21715086 DOI: 10.1016/J.Eururo.2011.06.034 |
0.351 |
|
| 2012 |
Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, Tannock IF. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urologic Oncology. 30: 607-13. PMID 20888271 DOI: 10.1016/J.Urolonc.2010.07.002 |
0.369 |
|
| 2012 |
Vera Badillo FE, Shapiro R, Ocana A, Amir E, Tannock I. Bias in reporting of endpoints of efficacy and toxicity in randomized clinical trials (RCTs) for women with breast cancer (BC). Journal of Clinical Oncology. 30: 6043-6043. DOI: 10.1200/Jco.2012.30.15_Suppl.6043 |
0.493 |
|
| 2012 |
Saggar JK, Tannock IF. Abstract 5247: Use of two markers of hypoxia to study migration, re-oxygenation and repopulation of originally hypoxic cells in MCF-7 tumor xenografts following chemotherapy Cancer Research. 72: 5247-5247. DOI: 10.1158/1538-7445.Am2012-5247 |
0.381 |
|
| 2012 |
Saggar JK, tannock iF. Abstract 5246: Use of γH2aX and other biomarkers to quantify distribution of drug activity in solid tumors Cancer Research. 72: 5246-5246. DOI: 10.1158/1538-7445.Am2012-5246 |
0.751 |
|
| 2012 |
Bernstein L, Seruga B, Pond G, Tirona K, Dodd A, Tannock I. Abstract P6-09-02: Pre-treatment cognitive function (CF) in women with locally advanced breast cancer (LABC) and in healthy controls. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-09-02 |
0.303 |
|
| 2012 |
Addison C, Zhao H, Mazzarello S, Mallick R, Amir E, Tannock I, Clemons M. Abstract P2-05-12: Effects of de-escalated bisphosphonate therapy on bone turnover or metastasis markers and their correlation with risk of skeletal related events – A biomarker analysis in conjunction with the REFORM study. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-05-12 |
0.435 |
|
| 2012 |
Booth C, Siemens D, Li G, Peng Y, Tannock I, Berman D, Kong W, Mackillop W. Neoadjuvant (NACT) and Adjuvant Chemotherapy (ACT) for Muscle-Invasive Bladder Cancer: A Population-Based Outcomes Study Annals of Oncology. 23: ix260. DOI: 10.1016/S0923-7534(20)33403-7 |
0.316 |
|
| 2012 |
Manji A, Garcia IB, Amir E, Tannock IF, Bedard P, Oza AM, Siu L, Razak ARA. Evolution of Clinical Trial Design in Early Drug Development: The Use of Expansion Cohorts (ECS) in Phase I Cancer Trials (PITS) Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33013-1 |
0.495 |
|
| 2011 |
Booth CM, Siemens DR, Tannock I, Peng Y, Li G, Mackillop WJ. Adoption of neoadjuvant (NACT) and adjuvant chemotherapy (ACT) for bladder cancer: A population-based study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4644. PMID 28023930 DOI: 10.1200/Jco.2011.29.15_Suppl.4644 |
0.338 |
|
| 2011 |
Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold LH, Berry WR, De Wit R, Eisenberger MA, Tannock I, Sonpavde G. Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4582. PMID 28023307 DOI: 10.1200/Jco.2011.29.15_Suppl.4582 |
0.376 |
|
| 2011 |
Vardy JL, Pond GR, Dodd A, Warr D, Seruga B, Clemons MJ, Bordeleau L, Tannock I. A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 9020. PMID 28021684 DOI: 10.1200/Jco.2011.29.15_Suppl.9020 |
0.322 |
|
| 2011 |
Niraula S, Emmeneger U, Adams L, Tannock I, Sridhar SS, Knox JJ, Day JR, Manthe J, Groskopf J, Joshua AM. Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 59. PMID 27968402 DOI: 10.1200/Jco.2011.29.7_Suppl.59 |
0.383 |
|
| 2011 |
Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, et al. Delivering affordable cancer care in high-income countries. The Lancet. Oncology. 12: 933-80. PMID 21958503 DOI: 10.1016/S1470-2045(11)70141-3 |
0.408 |
|
| 2011 |
Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3686-94. PMID 21844499 DOI: 10.1200/Jco.2010.34.3996 |
0.416 |
|
| 2011 |
Winocur G, Binns MA, Tannock I. Donepezil reduces cognitive impairment associated with anti-cancer drugs in a mouse model. Neuropharmacology. 61: 1222-8. PMID 21803055 DOI: 10.1016/J.Neuropharm.2011.07.013 |
0.318 |
|
| 2011 |
Amir E, Seruga B, Martinez-Lopez J, Kwong R, Pandiella A, Tannock IF, Ocaña A. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2543-9. PMID 21606435 DOI: 10.1200/Jco.2011.35.2393 |
0.444 |
|
| 2011 |
Niraula S, Tannock IF. Broadening horizons in medical management of prostate cancer. Acta Oncologica (Stockholm, Sweden). 50: 141-7. PMID 21604955 DOI: 10.3109/0284186X.2010.524936 |
0.385 |
|
| 2011 |
Beltran H, Beer TM, Carducci MA, De Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF. New therapies for castration-resistant prostate cancer: Efficacy and safety European Urology. 60: 279-290. PMID 21592649 DOI: 10.1016/J.Eururo.2011.04.038 |
0.374 |
|
| 2011 |
Sonpavde G, Pond GR, Berry WR, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer. 117: 3963-71. PMID 21365623 DOI: 10.1200/Jco.2011.29.7_Suppl.118 |
0.411 |
|
| 2011 |
Ocaña A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 254-6. PMID 21149670 DOI: 10.1200/Jco.2010.32.0275 |
0.485 |
|
| 2011 |
Ocana A, Pandiella A, Siu LL, Tannock IF. Preclinical development of molecular-targeted agents for cancer. Nature Reviews. Clinical Oncology. 8: 200-9. PMID 21135887 DOI: 10.1038/Nrclinonc.2010.194 |
0.353 |
|
| 2011 |
Seruga B, Sterling L, Wang L, Tannock IF. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 174-85. PMID 21135271 DOI: 10.1200/Jco.2010.31.9624 |
0.337 |
|
| 2011 |
Ocana A, Tannock IF. When are "positive" clinical trials in oncology truly positive? Journal of the National Cancer Institute. 103: 16-20. PMID 21131576 DOI: 10.1093/Jnci/Djq463 |
0.365 |
|
| 2011 |
Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nature Reviews. Clinical Oncology. 8: 12-23. PMID 20859283 DOI: 10.1038/Nrclinonc.2010.136 |
0.416 |
|
| 2011 |
Sridhar SS, Winquist E, Eisen A, Hotte SJ, McWhirter E, Tannock IF, Mukherjee SD, Wang L, Blattler C, Wright JJ, Moore MJ. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Investigational New Drugs. 29: 1045-9. PMID 20191303 DOI: 10.1007/S10637-010-9408-4 |
0.368 |
|
| 2011 |
Niraula S, Amir E, Ocana A, Seruga B, Tannock I. The balance between benefits and harms of molecular targeted agents. Journal of Clinical Oncology. 29: 6030-6030. DOI: 10.1200/Jco.2011.29.15_Suppl.6030 |
0.467 |
|
| 2011 |
Alibhai SMH, Breunis H, Timilshina N, Duff Canning S, Fleshner N, Krahn M, Tannock I, Tomlinson GA, Warde PR, Naglie G. Impact of 24 months of androgen deprivation therapy (ADT) on physical function in men with nonmetastatic prostate cancer. Journal of Clinical Oncology. 29: 4640-4640. DOI: 10.1200/Jco.2011.29.15_Suppl.4640 |
0.323 |
|
| 2011 |
Seruga B, Horgan AM, Pond GR, Alibhai SMH, Amir E, De Wit R, Eisenberger MA, Tannock I. Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. Journal of Clinical Oncology. 29: 4530-4530. DOI: 10.1200/Jco.2011.29.15_Suppl.4530 |
0.515 |
|
| 2011 |
Saggar JK, Tannock IF. Abstract 560: The use of molecular biomarkers to quantify drug distribution in solid tumors Cancer Research. 71: 560-560. DOI: 10.1158/1538-7445.Am2011-560 |
0.386 |
|
| 2011 |
Tan Q, Patel K, Lee CM, Zhang J, Joshua A, Koritzinsky M, Wouters BG, Tannock IF. Abstract 537: Mechanisms by which pantoprazole, a proton pump inhibitor, enhances the activity of doxorubicin in solid tumors Cancer Research. 71: 537-537. DOI: 10.1158/1538-7445.Am2011-537 |
0.393 |
|
| 2011 |
Richter S, Tran B, Patel K, Ocana A, Wang L, Haines C, Recel M, Chen EX, Tannock IF, Siu LL, Bedard PL. Abstract C25: A phase I study evaluating the proton pump inhibitor pantoprazole (PTP) in combination with doxorubicin (DOX) for advanced cancer patients (pts). Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C25 |
0.359 |
|
| 2011 |
Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol N, Amir E, Khayat D, Boyle P, Tannock I, Fojo T. Delivering Affordable Cancer Care in High-income Countries: a Lancet Oncology Commission European Journal of Cancer. 47: 6. DOI: 10.1016/S0959-8049(11)70107-1 |
0.451 |
|
| 2010 |
Alibhai SMH, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, Krahn M, Fleshner NE, Warde P, Canning SD, Klotz L, Naglie G. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer Journal of Clinical Oncology. 28: 5038-5045. PMID 21041715 DOI: 10.1200/Jco.2010.29.8091 |
0.32 |
|
| 2010 |
Alibhai SMH, Breunis H, Timilshina N, Marzouk S, Stewart D, Tannock I, Naglie G, Tomlinson G, Fleshner N, Krahn M, Warde P, Canning SD. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer Journal of Clinical Oncology. 28: 5030-5037. PMID 21041708 DOI: 10.1200/Jco.2010.30.8742 |
0.333 |
|
| 2010 |
Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4247-54. PMID 20733135 DOI: 10.1200/Jco.2009.26.8771 |
0.385 |
|
| 2010 |
Momm F, Kaden M, Tannock I, Schumacher M, Hasse J, Henke M. Dose escalation of gemcitabine concomitant with radiation and cisplatin for nonsmall cell lung cancer: a phase 1-2 study. Cancer. 116: 4833-9. PMID 20589760 DOI: 10.1002/Cncr.25366 |
0.311 |
|
| 2010 |
Lee CM, Tannock IF. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. Bmc Cancer. 10: 255. PMID 20525277 DOI: 10.1186/1471-2407-10-255 |
0.315 |
|
| 2010 |
Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 203-11. PMID 20008841 DOI: 10.1158/1078-0432.Ccr-09-2514 |
0.379 |
|
| 2010 |
Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. European Journal of Cancer (Oxford, England : 1990). 46: 517-25. PMID 20005697 DOI: 10.1016/J.Ejca.2009.11.007 |
0.324 |
|
| 2010 |
Seruga B, Hertz PC, Le LW, Tannock IF. Global drug development in cancer: a cross-sectional study of clinical trial registries. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 895-900. PMID 19815650 DOI: 10.1200/Jco.2009.27.15_Suppl.2520 |
0.37 |
|
| 2010 |
Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. The American Journal of Hospice & Palliative Care. 27: 106-10. PMID 19776373 DOI: 10.1177/1049909109345685 |
0.319 |
|
| 2010 |
Alibhai SM, Marzouk S, Naglie G, Tannock I, Tomlinson GA, Timilshina N, Stewart D, Fleshner N, Warde PR, Duff Canning S. Impact of 12 months of androgen-deprivation therapy (ADT) on cognitive function in men with nonmetastatic prostate cancer (PC): A matched cohort study. Journal of Clinical Oncology. 28: 9027-9027. DOI: 10.1200/Jco.2010.28.15_Suppl.9027 |
0.359 |
|
| 2010 |
Seruga B, Sterling L, Wang L, Tannock I. Reporting of serious toxicities of targeted cancer drugs in published reports of randomized phase III clinical trials (RCTs). Journal of Clinical Oncology. 28: 6028-6028. DOI: 10.1200/Jco.2010.28.15_Suppl.6028 |
0.384 |
|
| 2010 |
Pond GR, Sonpavde G, Berry WR, De Wit R, Armstrong AJ, Eisenberger MA, Tannock I. Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial. Journal of Clinical Oncology. 28: 4637-4637. DOI: 10.1200/Jco.2010.28.15_Suppl.4637 |
0.378 |
|
| 2010 |
Marzouk S, Duff Canning S, Naglie G, Tomlinson GA, Leach M, Hussain F, Tannock I, Alibhai SM. The effect of ADT on objective cognitive performance and self-reported cognitive functionin men with prostate cancer. Journal of Clinical Oncology. 28: 4560-4560. DOI: 10.1200/Jco.2010.28.15_Suppl.4560 |
0.353 |
|
| 2009 |
Armstrong AJ, Halabi S, Tannock IF, George DJ, DeWit R, Eisenberger M. Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5137. PMID 27964425 DOI: 10.1200/Jco.2009.27.15_Suppl.5137 |
0.365 |
|
| 2009 |
Seruga B, Hertz PC, Wang L, Booth CM, Krzyzanowska M, Cescon DW, Tannock IF. Absolute benefits of experimental medical therapies in phase III randomized clinical trials (RCTs) in breast and colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6513. PMID 27964019 DOI: 10.1200/Jco.2009.27.15_Suppl.6513 |
0.331 |
|
| 2009 |
Vardy JL, Dhillon H, Xu W, Dodd A, Park A, Rourke SB, Clarke SJ, Ringash J, Burkes R, Tannock IF. Cognitive function and fatigue in colorectal cancer (CRC) patients: Baseline assessments prior to chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 9557. PMID 27963642 DOI: 10.1200/Jco.2009.27.15_Suppl.9557 |
0.33 |
|
| 2009 |
Sridhar SS, Canil CM, Eisen A, Tannock IF, Knox JJ, Reaume N, Mukherjee SD, Winquist E, Chung A, Ko YJ. A phase II study of single agent abraxane as second-line therapy in patients with advanced urothelial carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e16058. PMID 27963001 DOI: 10.1200/Jco.2009.27.15_Suppl.E16058 |
0.343 |
|
| 2009 |
Cescon DW, Canil C, Le LW, Tannock IF. Use of the Prostate Cancer-specific Quality of Life Instrument (PROSQOLI) in clinical practice. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e20569. PMID 27961125 DOI: 10.1200/Jco.2009.27.15_Suppl.E20569 |
0.328 |
|
| 2009 |
Seruga B, Amir E, Tannock I. Treatment of lung cancer. The New England Journal of Medicine. 361: 2485; author reply 2. PMID 20050212 DOI: 10.1056/NEJMc0909634 |
0.376 |
|
| 2009 |
Amir E, Tannock IF. Prostate cancer: Androgen deprivation therapy and bone loss. Nature Reviews. Urology. 6: 642-4. PMID 19956194 DOI: 10.1038/Nrurol.2009.218 |
0.482 |
|
| 2009 |
Seruga B, Hertz PC, Wang L, Booth CM, Cescon DW, Krzyzanowska M, Tannock IF. Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 21: 1411-1418. PMID 19951955 DOI: 10.1093/Annonc/Mdp552 |
0.331 |
|
| 2009 |
Patel KJ, Tannock IF. The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. Bmc Cancer. 9: 356. PMID 19807929 DOI: 10.1186/1471-2407-9-356 |
0.392 |
|
| 2009 |
Fung AS, Wu L, Tannock IF. Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5389-95. PMID 19706800 DOI: 10.1158/1078-0432.Ccr-08-3007 |
0.388 |
|
| 2009 |
Amir E, Seruga B, Freedman O, Tannock I. Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1919; author reply 1. PMID 19255302 DOI: 10.1200/Jco.2008.21.2951 |
0.484 |
|
| 2009 |
Trédan O, Garbens AB, Lalani AS, Tannock IF. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Research. 69: 940-7. PMID 19176397 DOI: 10.1158/0008-5472.Can-08-0676 |
0.375 |
|
| 2009 |
Seruga B, Tannock IF. Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 840-2. PMID 19139426 DOI: 10.1200/Jco.2008.19.5594 |
0.403 |
|
| 2009 |
Armstrong AJ, Halabi S, de Wit R, Tannock IF, Eisenberger M. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer Prostate Cancer and Prostatic Diseases. 12: 88-93. PMID 18574490 DOI: 10.1200/Jco.2008.26.15_Suppl.5074 |
0.309 |
|
| 2009 |
Fan HG, Park A, Xu W, Yi QL, Braganza S, Chang J, Couture F, Tannock IF. The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psycho-Oncology. 18: 156-61. PMID 18561284 DOI: 10.1002/Pon.1372 |
0.336 |
|
| 2009 |
Chi K, Hotte S, Yu E, Tu D, Eigl B, Tannock I, Saad F, North S, Powers J, Eisenhauer E. 7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC) European Journal of Cancer Supplements. 7: 407. DOI: 10.1016/S1359-6349(09)71382-5 |
0.379 |
|
| 2008 |
Chow E, Abdolell M, Panzarella T, Harris K, Bezjak A, Warde P, Tannock I. Predictive model for survival in patients with advanced cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5863-9. PMID 19018082 DOI: 10.1200/Jco.2008.17.1363 |
0.35 |
|
| 2008 |
Seruga B, Tannock IF. The changing face of hormonal therapy for prostate cancer Annals of Oncology. 19. PMID 18790984 DOI: 10.1093/Annonc/Mdn477 |
0.322 |
|
| 2008 |
Seruga B, Tannock IF. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nature Clinical Practice. Oncology. 5: 574-6. PMID 18628739 DOI: 10.1038/Ncponc1180 |
0.358 |
|
| 2008 |
Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 1749-53. PMID 18487550 DOI: 10.1093/Annonc/Mdn288 |
0.382 |
|
| 2008 |
Seruga B, Tannock IF. Mathematics in the realm of lapatinib: 500 + 500 = 1,500? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2940-2. PMID 18458041 DOI: 10.1200/Jco.2008.16.5282 |
0.399 |
|
| 2008 |
Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, Knox JJ. Sorafenib for metastatic renal cancer: the Princess Margaret experience. American Journal of Clinical Oncology. 31: 182-7. PMID 18391604 DOI: 10.1097/Coc.0B013E3181574084 |
0.322 |
|
| 2008 |
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1148-59. PMID 18309951 DOI: 10.1200/Jco.2007.12.4487 |
0.386 |
|
| 2008 |
Booth CM, Tannock I. Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 6-8. PMID 18165630 DOI: 10.1200/Jco.2007.13.8156 |
0.316 |
|
| 2008 |
Mar Fan HG, Clemons M, Xu W, Chemerynsky I, Breunis H, Braganza S, Tannock IF. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 16: 577-83. PMID 17972110 DOI: 10.1007/S00520-007-0341-9 |
0.321 |
|
| 2008 |
Breunis H, Leach M, Naglie G, Tannock IF, Fleshner NE, Krahn M, Duff-Canning S, Tomlinson G, Warde P, Alibhai SM. Androgen deprivation therapy (ADT) and physical function in men with nonmetastatic prostate cancer Journal of Clinical Oncology. 26: 5130-5130. DOI: 10.1200/Jco.2008.26.15_Suppl.5130 |
0.311 |
|
| 2007 |
Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6396-403. PMID 17975152 DOI: 10.1158/1078-0432.Ccr-07-1036 |
0.353 |
|
| 2007 |
Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, Eisenberger M. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3965-70. PMID 17761981 DOI: 10.1200/Jco.2007.11.4769 |
0.33 |
|
| 2007 |
Joly F, Vardy J, Pintilie M, Tannock IF. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer Annals of Oncology. 18: 1935-1942. PMID 17698837 DOI: 10.1093/Annonc/Mdm121 |
0.325 |
|
| 2007 |
Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. Journal of the National Cancer Institute. 99: 592-600. PMID 17440160 DOI: 10.1093/Jnci/Djk130 |
0.333 |
|
| 2007 |
Vardy JL, Booth C, Pond GR, Zhang H, Galica J, Dhillon H, Clarke SJ, Tannock IF. Cytokine levels in patients (pts) with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function Journal of Clinical Oncology. 25: 9070-9070. DOI: 10.1200/Jco.2007.25.18_Suppl.9070 |
0.308 |
|
| 2007 |
Cescon DW, Booth CM, Wang L, Tannock IF, Krzyzanowska MK. Trends in the quality of abstracts of articles describing randomized controlled cancer trials (RCTs) from 1975–2004 Journal of Clinical Oncology. 25: 6541-6541. DOI: 10.1200/Jco.2007.25.18_Suppl.6541 |
0.308 |
|
| 2007 |
Eisenberger M, Garrett-Mayer ES, Yang YO, Wit Rd, Tannock I, Armstrong AJ. A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC) Journal of Clinical Oncology. 25: 5058-5058. DOI: 10.1200/Jco.2007.25.18_Suppl.5058 |
0.357 |
|
| 2007 |
Scher HI, Halabi S, Tannock I, Morris M, Higano C, Kelly W, Sternberg C, Eisenberger M, Martin A, Hussain M. The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer Journal of Clinical Oncology. 25: 5057-5057. DOI: 10.1200/Jco.2007.25.18_Suppl.5057 |
0.374 |
|
| 2007 |
Armstrong AJ, Eisenberger MA, Garrett-Mayer ES, Ou Yang Y, Carducci MA, de Wit R, Tannock I. Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC) Journal of Clinical Oncology. 25: 5009-5009. DOI: 10.1200/Jco.2007.25.18_Suppl.5009 |
0.382 |
|
| 2007 |
Chin S, Riechelmann RP, Wang L, Tannock IF, Berthold DR, Moore M, Knox JJ. Sorafenib for the treatment of metastatic renal cancer (MRC) in the real world: The Princess Margaret Hospital (PMH) experience Journal of Clinical Oncology. 25: 15568-15568. DOI: 10.1200/Jco.2007.25.18_Suppl.15568 |
0.313 |
|
| 2006 |
Joly F, Alibhai SMH, Galica J, Park A, Yi QL, Wagner L, Tannock IF. Impact of Androgen Deprivation Therapy on Physical and Cognitive Function, as Well as Quality of Life of Patients With Nonmetastatic Prostate Cancer Journal of Urology. 176: 2443-2447. PMID 17085125 DOI: 10.1016/J.Juro.2006.07.151 |
0.346 |
|
| 2006 |
Winocur G, Vardy J, Binns MA, Kerr L, Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacology, Biochemistry, and Behavior. 85: 66-75. PMID 16935324 DOI: 10.1016/J.Pbb.2006.07.010 |
0.327 |
|
| 2006 |
Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. British Journal of Cancer. 94: 1011-5. PMID 16552437 DOI: 10.1200/Jco.2005.23.16_Suppl.8017 |
0.356 |
|
| 2006 |
Brade AM, Tannock IF. Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1020-2. PMID 16505418 DOI: 10.1200/Jco.2005.04.9676 |
0.408 |
|
| 2006 |
Lee CM, Tannock IF. Inhibition of endosomal sequestration of basic anticancer drugs: Influence on cytotoxicity and tissue penetration British Journal of Cancer. 94: 863-869. PMID 16495919 DOI: 10.1038/Sj.Bjc.6603010 |
0.331 |
|
| 2006 |
Downie FP, Mar Fan HG, Houédé-Tchen N, Yi Q, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psycho-Oncology. 15: 921-30. PMID 16477674 DOI: 10.1002/Pon.1035 |
0.3 |
|
| 2006 |
Berthold DR, Tannock IF. Are prostate cancer clinical trial enrollment criteria and endpoints appropriate? Nature Clinical Practice. Oncology. 3: 74-5. PMID 16462843 DOI: 10.1038/Ncponc0425 |
0.373 |
|
| 2006 |
Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Research. 66: 1033-9. PMID 16424039 DOI: 10.1158/0008-5472.Can-05-3077 |
0.376 |
|
| 2006 |
Riechelmann RP, Wang L, Tannock IF, Krzyzanowska MK. Drug interactions in ambulatory cancer patients receiving cancer-directed therapy Journal of Clinical Oncology. 24: 6129-6129. DOI: 10.1200/Jco.2006.24.18_Suppl.6129 |
0.39 |
|
| 2006 |
Gogov S, Hussain F, Naglie G, Tannock I, Fleshner NE, Krahn MD, Duff Canning S, Warde P, Alibhai SM. Is physical function affected by androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer? Journal of Clinical Oncology. 24: 4615-4615. DOI: 10.1200/Jco.2006.24.18_Suppl.4615 |
0.32 |
|
| 2005 |
Joly F, Alibhai S, Galica J, Soban F, Park A, Yi QL, Wagner L, Tannock I. Impact of androgen deprivation therapy (ADT) on quality of life (QL), cognitive and physical function of patients with non-metastatic prostate cancer (PC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4627. PMID 27947005 DOI: 10.1200/Jco.2005.23.16_Suppl.4627 |
0.324 |
|
| 2005 |
Roessner M, de Wit R, Tannock IF, Yateman N, Yao SL, Yver A, Eisenberger MA. Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4554. PMID 27946377 DOI: 10.1200/Jco.2005.23.16_Suppl.4554 |
0.358 |
|
| 2005 |
Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8782-8. PMID 16361566 DOI: 10.1158/1078-0432.Ccr-05-1664 |
0.361 |
|
| 2005 |
Wu L, Tannock IF. Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8195-200. PMID 16299252 DOI: 10.1158/1078-0432.Ccr-05-1258 |
0.39 |
|
| 2005 |
Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8247-52. PMID 16278480 DOI: 10.1200/Jco.2005.03.1435 |
0.352 |
|
| 2005 |
Meyskens FL, Hietanen P, Tannock IF. Talking to a patient. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4463-4. PMID 15994158 DOI: 10.1200/Jco.2005.04.002 |
0.306 |
|
| 2005 |
Wong P, Lee C, Tannock IF. Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells Clinical Cancer Research. 11: 3553-3557. PMID 15867259 DOI: 10.1158/1078-0432.Ccr-04-2472 |
0.395 |
|
| 2005 |
Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts Cancer Research. 65: 2825-2831. PMID 15805283 DOI: 10.1158/0008-5472.Can-04-3137 |
0.403 |
|
| 2005 |
Tannock IF, Primeau A, Grantab R, Lee C. Limited penetration of anticancer drugs to cells in solid tumors: A neglected and modifiable cause of drug resistance Journal of Clinical Oncology. 23: 9563-9563. DOI: 10.1200/Jco.2005.23.16_Suppl.9563 |
0.353 |
|
| 2005 |
Alibhai SMH, Gogov S, Tannock I, Chemerynsky I, Park A, Homer M, Fleshner NE, Naglie G, Krahn MD, Duff Canning S. Relationship between sex hormones and cognition in men with and without prostate cancer Journal of Clinical Oncology. 23: 4619-4619. DOI: 10.1200/Jco.2005.23.16_Suppl.4619 |
0.317 |
|
| 2004 |
Tchen N, Juffs HG, Yi QL, Chemerynsky I, Downie FP, Sabate K, Tannock IF. Cognitive function, fatigue and menopausal symptoms in women following adjuvant chemotherapy for breast cancer: One and two year follow-up of a prospective controlled study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 8001. PMID 28015817 DOI: 10.1200/Jco.2004.22.14_Suppl.8001 |
0.311 |
|
| 2004 |
Eisenberger MA, De Wit R, Berry W, Bodrogi I, Pluzanska A, Chi K, Oudard S, Christine T, James N, Tannock I. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4. PMID 28014163 DOI: 10.1200/Jco.2004.22.14_Suppl.4 |
0.343 |
|
| 2004 |
Joly F, Tannock IF. Chemotherapy for patients with hormone-refractory prostate cancer Annals of Oncology. 15: 1582-1584. PMID 15520057 DOI: 10.1093/Annonc/Mdh445 |
0.368 |
|
| 2004 |
Vardy J, Tannock IF. Quality of cancer care Annals of Oncology. 15: 1001-1006. PMID 15205191 DOI: 10.1093/Annonc/Mdh275 |
0.343 |
|
| 2004 |
Vallis KA, Tannock IF. Postoperative radiotherapy for breast cancer: Growing evidence for an impact on survival Journal of the National Cancer Institute. 96: 88-89. PMID 14734691 DOI: 10.1093/Jnci/Djh029 |
0.334 |
|
| 2004 |
Davis AJ, Chapman W, Hedley DW, Oza AM, Tannock IF. Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 51: 1-6. PMID 12500299 DOI: 10.1002/Cyto.A.10001 |
0.392 |
|
| 2004 |
Bahl M, Siu LL, Pond GR, Kim J, Tannock IF, Bayley A, Cummings B, Waldron J, Ringash J, O'Sullivan B. Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status Journal of Clinical Oncology. 22: 5572-5572. DOI: 10.1200/Jco.2004.22.90140.5572 |
0.375 |
|
| 2004 |
Chung P, Gospodarowicz M, Warde P, Qi-Long Y, Jewett M, Milosevic M, Bristow R, Moore M, Tannock I, McLean M. Long-term effects of conservation therapy for muscle invasive bladder carcinoma Journal of Clinical Oncology. 22: 4519-4519. DOI: 10.1200/Jco.2004.22.90140.4519 |
0.324 |
|
| 2003 |
Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 3335-42. PMID 12947070 DOI: 10.1200/Jco.2003.03.042 |
0.375 |
|
| 2003 |
Krzyzanowska MK, Pintilie M, Tannock IF. Factors Associated with Failure to Publish Large Randomized Trials Presented at an Oncology Meeting Journal of the American Medical Association. 290: 495-501. PMID 12876092 DOI: 10.1001/Jama.290.4.495 |
0.306 |
|
| 2003 |
Townsley CA, Chi K, Ernst DS, Belanger K, Tannock I, Bjarnason GA, Stewart D, Goel R, Ruether JD, Siu LL, Jolivet J, McIntosh L, Seymour L, Moore MJ. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1524-9. PMID 12697876 DOI: 10.1200/Jco.2003.03.057 |
0.352 |
|
| 2003 |
Chvetzoff G, Tannock IF. Placebo effects in oncology Journal of the National Cancer Institute. 95: 19-29. PMID 12509397 DOI: 10.1093/Jnci/95.1.19 |
0.341 |
|
| 2003 |
Tannock IF. From evidence-based medicine to clinical practice: Not always straightforward European Journal of Cancer, Supplement. 1: 93-101. DOI: 10.1016/S1359-6349(03)90013-9 |
0.34 |
|
| 2002 |
Davis AJ, Tannock IF. Tumor physiology and resistance to chemotherapy: repopulation and drug penetration Cancer Treatment and Research. 112: 1-26. PMID 12481709 DOI: 10.1007/978-1-4615-1173-1_1 |
0.434 |
|
| 2002 |
Juffs HG, Moore MJ, Tannock IF. The role of systemic chemothearapy in the management of muscle-invasive bladder cancer Lancet Oncology. 3: 738-747. PMID 12473515 DOI: 10.1016/S1470-2045(02)00930-0 |
0.375 |
|
| 2002 |
Lofters A, Juffs HG, Pond GR, Tannock IF. "PSA-ITIS": Knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer Journal of Urology. 168: 2516-2520. PMID 12441952 DOI: 10.1016/S0022-5347(05)64180-8 |
0.346 |
|
| 2002 |
Canil CM, Tannock IF. Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone? Journal of the National Cancer Institute. 94: 1422-1423. PMID 12359844 DOI: 10.1093/Jnci/94.19.1422 |
0.363 |
|
| 2002 |
Tannock IF. Eradication of a disease: How we cured symptomless prostate cancer Lancet. 359: 1341-1342. PMID 11965297 DOI: 10.1016/S0140-6736(02)08278-8 |
0.367 |
|
| 2002 |
Dowling AJ, Panzarella T, Ernst DS, Neville AJ, Moore MJ, Tannock IF. A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 12: 773-8. PMID 11484951 DOI: 10.1023/A:1011116626590 |
0.361 |
|
| 2001 |
Tannock IF. Tumor physiology and drug resistance Cancer and Metastasis Reviews. 20: 123-132. PMID 11831640 DOI: 10.1023/A:1013125027697 |
0.373 |
|
| 2001 |
Tannock IF. Removing the primary tumor after the cancer has spread New England Journal of Medicine. 345: 1699-1700. PMID 11759650 DOI: 10.1056/Nejm200112063452310 |
0.351 |
|
| 2001 |
Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma Cancer. 91: 2246-2257. PMID 11413512 DOI: 10.1002/1097-0142(20010615)91:12<2246::Aid-Cncr1255>3.0.Co;2-4 |
0.334 |
|
| 2001 |
Tannock IF. Collaborative Clinical trials: Quality or quantity? International Journal of Radiation Oncology Biology Physics. 49: 339-343. PMID 11173126 DOI: 10.1016/S0360-3016(00)01500-5 |
0.361 |
|
| 2001 |
Tannock IF, Lee C. Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs British Journal of Cancer. 84: 100-105. PMID 11139321 DOI: 10.1054/Bjoc.2000.1538 |
0.368 |
|
| 2000 |
Davis AJ, Tannock IF. Repopulation of tumour cells between cycles of chemotherapy: A neglected factor Lancet Oncology. 1: 86-93. PMID 11905673 DOI: 10.1016/S1470-2045(00)00019-X |
0.34 |
|
| 2000 |
Wilson KA, Dowling AJ, Abdolell M, Tannock IF. Perception of quality of life by patients, partners and treating physicians Quality of Life Research. 9: 1041-1052. PMID 11332225 DOI: 10.1023/A:1016647407161 |
0.357 |
|
| 2000 |
Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, Walsh W, Seymour L. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 2876-81. PMID 10561365 DOI: 10.1200/Jco.1999.17.9.2876 |
0.393 |
|
| 2000 |
Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1654-63. PMID 10561201 DOI: 10.1200/Jco.1999.17.6.1654 |
0.34 |
|
| 2000 |
Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 3082-90. PMID 10506603 DOI: 10.1200/Jco.1999.17.10.3082 |
0.354 |
|
| 2000 |
Tannock IF. Eradication of a disease: how we cured asymptomatic prostate cancer The Lancet Oncology. 1: 17-19. DOI: 10.1016/S1470-2045(09)70279-7 |
0.332 |
|
| 1999 |
McLachlan SA, Pintilie M, Tannock IF. Third line chemotherapy in patients with metastatic breast cancer: An evaluation of quality of life and cost Breast Cancer Research and Treatment. 54: 213-223. PMID 10445420 DOI: 10.1023/A:1006123721205 |
0.354 |
|
| 1999 |
Stockler MR, Osoba D, Corey P, Goodwin PJ, Tannock IF. convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module Journal of Clinical Epidemiology. 52: 653-666. PMID 10391659 DOI: 10.1016/S0895-4356(99)00025-6 |
0.343 |
|
| 1999 |
Tunggal JK, Ballinger JR, Tannock IF. Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents. International Journal of Cancer. 81: 741-7. PMID 10328227 DOI: 10.1002/(Sici)1097-0215(19990531)81:5<741::Aid-Ijc13>3.0.Co;2-G |
0.313 |
|
| 1998 |
Tannock IF. Conventional cancer therapy: Promise broken or promise delayed? Lancet. 351. PMID 9606361 DOI: 10.1016/S0140-6736(98)90327-0 |
0.323 |
|
| 1998 |
Stockler MR, Osoba D, Goodwin P, Corey P, Tannock IF. Responsiveness to change in health-related quality of life in a randomized clinical trial: A comparison of the prostate cancer specific quality of life instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module Journal of Clinical Epidemiology. 51: 137-145. PMID 9474074 DOI: 10.1016/S0895-4356(97)00269-2 |
0.373 |
|
| 1998 |
Tannock IF. The role of clinical trials and their impact on breast cancer management European Journal of Cancer. 34: S128. DOI: 10.1016/S0959-8049(98)80544-3 |
0.331 |
|
| 1998 |
Panzarella T, Dowling AJ, Tannock IF. Analysis of survival by palliative response in patients with symptomatic hormone refractory prostate cancer Controlled Clinical Trials. 19: S77. DOI: 10.1016/S0197-2456(98)80187-6 |
0.362 |
|
| 1998 |
CZAYKOWSKI PM, MOORE MJ, TANNOCK IF. HIGH RISK OF VASCULAR EVENTS IN PATIENTS WITH UROTHELIAL TRANSITIONAL CELL CARCINOMA TREATED WITH CISPLATIN BASED CHEMOTHERAPY Journal of Urology. 160: 2021-2024. DOI: 10.1016/S0022-5347(01)62232-8 |
0.32 |
|
| 1997 |
Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 3441-5. PMID 9396395 DOI: 10.1200/Jco.1997.15.12.3441 |
0.35 |
|
| 1997 |
Bloomfield D, Krahn M, Willan A, Tannock I. OP5. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone resistant prostate cancer based on a Canadian randomised trial with palliative endpoints European Journal of Cancer. 33: S2. DOI: 10.1016/S0959-8049(97)85884-4 |
0.392 |
|
| 1995 |
Doyle C, Tannock IF. Adjuvant radiation or systemic therapy for renal cell carcinoma: A brief review Urologic Oncology: Seminars and Original Investigations. 1: 161-165. DOI: 10.1016/1078-1439(95)00055-0 |
0.332 |
|
| 1994 |
Tannock IF. New perspectives in combined radiotherapy and chemotherapy treatment Lung Cancer. 10. PMID 7522114 DOI: 10.1016/0169-5002(94)91665-9 |
0.396 |
|
| 1994 |
Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 689-94. PMID 7512127 DOI: 10.1200/Jco.1994.12.4.689 |
0.372 |
|
| 1993 |
Boyer MJ, Tannock IF. Lysosomes, lysosomal enzymes, and cancer Advances in Cancer Research. 60: 269-291. PMID 8417501 DOI: 10.1016/S0065-230X(08)60828-3 |
0.317 |
|
| 1992 |
Tannock IF. Some problems related to the design and analysis of clinical trials International Journal of Radiation Oncology, Biology, Physics. 22: 881-885. PMID 1555980 DOI: 10.1016/0360-3016(92)90783-E |
0.335 |
|
| 1991 |
Dobrowsky E, Newell K, Tannock IF. The potential of lactate and succinate to kill nutrient deprived tumor cells by intracellular acidification International Journal of Radiation Oncology, Biology, Physics. 20: 275-279. PMID 1991688 DOI: 10.1016/0360-3016(91)90104-C |
0.31 |
|
| 1991 |
Choo R, Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the Princess Margaret Hospital experience. Cancer. 68: 2120-4. PMID 1913449 DOI: 10.1002/1097-0142(19911115)68:10<2120::Aid-Cncr2820681005>3.0.Co;2-7 |
0.355 |
|
| 1991 |
Luk CK, Tannock IF. Evaluation of the probability of spontaneous transfer of drug resistance between cells in culture In Vitro Cellular and Developmental Biology - Animal. 27: 245-248. PMID 1903383 DOI: 10.1007/Bf02630924 |
0.315 |
|
| 1990 |
Tannock IF, Boyer M. When is a cancer treatment worthwhile? New England Journal of Medicine. 323: 989-990. PMID 2169589 DOI: 10.1056/Nejm199010043231410 |
0.332 |
|
| 1990 |
Luk CK, Veinot-drebot L, Tjan E, Tannock IF. Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines Journal of the National Cancer Institute. 82: 684-692. PMID 1969493 DOI: 10.1093/Jnci/82.8.684 |
0.314 |
|
| 1989 |
Tannock I, Gospodarowicz M, Connolly J, Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. The Journal of Urology. 142: 289-92. PMID 2746745 DOI: 10.1016/S0022-5347(17)38733-5 |
0.33 |
|
| 1989 |
Baar J, Tannock I. Analyzing the same data in two ways: a demonstration model to illustrate the reporting and misreporting of clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 969-78. PMID 2738626 DOI: 10.1200/Jco.1989.7.7.969 |
0.346 |
|
| 1989 |
Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 590-7. PMID 2709088 DOI: 10.1200/Jco.1989.7.5.590 |
0.324 |
|
| 1989 |
Tannock IF. Combined modality treatment with radiotherapy and chemotherapy Radiotherapy and Oncology. 16: 83-101. PMID 2687956 DOI: 10.1016/0167-8140(89)90025-X |
0.41 |
|
| 1989 |
Luk CK, Tannock IF. Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines Journal of the National Cancer Institute. 81: 55-59. PMID 2642304 DOI: 10.1093/Jnci/81.1.55 |
0.34 |
|
| 1989 |
Tannock IF, Rotin D. Acid pH in Tumors and Its Potential for Therapeutic Exploitation Cancer Research. 49: 4373-4384. PMID 2545340 |
0.503 |
|
| 1988 |
Tannock IF, Rotin D. Keynote Address: Mechanisms of interaction between radiation and drugs with potential for improvements in therapy Nci Monographs. 77-83. PMID 3352792 |
0.511 |
|
| 1988 |
Tannock I, Warr D. Nonrandomized clinical trials of cancer chemotherapy: phase II or III? Journal of the National Cancer Institute. 80: 800-1. PMID 3292772 DOI: 10.1093/Jnci/80.11.800 |
0.346 |
|
| 1988 |
Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, Mayers C, Perrault D, Sutherland H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 6: 1377-87. PMID 2458438 DOI: 10.1200/Jco.1988.6.9.1377 |
0.314 |
|
| 1987 |
Tannock IF. Toxicity of 5-fluorouracil for aerobic and hypoxic cells in two murine tumours Cancer Chemotherapy and Pharmacology. 19: 53-56. PMID 3815727 DOI: 10.1007/Bf00296256 |
0.317 |
|
| 1987 |
Tannock IF. Treating the patient, not just the cancer New England Journal of Medicine. 317: 1534-1535. PMID 3683488 DOI: 10.1056/Nejm198712103172409 |
0.425 |
|
| 1987 |
Tannock I, Payne D, Cummings B, Hewitt K, Panzarella T. Sequential chemotherapy and radiation for nasopharyngeal cancer: absence of long-term benefit despite a high rate of tumor response to chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 5: 629-34. PMID 3549991 DOI: 10.1200/Jco.1987.5.4.629 |
0.357 |
|
| 1986 |
Rotin D, Tannock IF, Robinson B. Influence of Hypoxia and an Acidic Environment on the Metabolism and Viability of Cultured Cells: Potential Implications for Cell Death in Tumors Cancer Research. 46: 2821-2826. PMID 3698008 |
0.512 |
|
| 1986 |
Tannock IF. Experimental chemotherapy and concepts related to the cell cycle International Journal of Radiation Biology. 49: 335-355. PMID 3510996 DOI: 10.1080/09553008514552581 |
0.353 |
|
| 1985 |
Tonkin K, Tritchler D, Tannock I. Criteria of tumor response used in clinical trials of chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 3: 870-5. PMID 4009220 DOI: 10.1200/Jco.1985.3.6.870 |
0.4 |
|
| 1985 |
Tonkin K, Tannock I. Dose Intensity in Chemotherapy Journal of Clinical Oncology. 3: 891-891. DOI: 10.1200/Jco.1985.3.6.891 |
0.36 |
|
| 1984 |
Tannock I, Choo B, Buick R. The radiation response of human bladder cancer assessed in vitro or as xenografts in immune-deprived mice International Journal of Radiation Oncology, Biology, Physics. 10: 1897-1902. PMID 6490419 DOI: 10.1016/0360-3016(84)90269-4 |
0.323 |
|
| 1984 |
Rotin D, Tannock IF. The effect of the drug lonidamine on chinese hamster ovary cells in vitro and on experimental tumors International Journal of Radiation Oncology, Biology, Physics. 10: 1595-1598. PMID 6480446 DOI: 10.1016/0360-3016(84)90509-1 |
0.613 |
|
| 1983 |
Tannock IF, Gospodarowicz M, Evans WK. Chemotherapy for metastatic transitional carcinoma of the urinary tract. A prospective trial of methotrexate, Adriamycin, and cyclophosphamide (MAC) with cis-platinum for failure Cancer. 51: 216-219. PMID 6681591 DOI: 10.1002/1097-0142(19830115)51:2<216::Aid-Cncr2820510208>3.0.Co;2-I |
0.316 |
|
| 1983 |
Tannock IF. Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract Cancer Treatment Reports. 67: 503-504. PMID 6406061 DOI: 10.1016/S0022-5347(17)50271-2 |
0.329 |
|
| 1983 |
Tannock IF. Biology of tumor growth Hospital Practice. 18: 81-93. PMID 6404785 DOI: 10.1080/21548331.1983.11702514 |
0.348 |
|
| 1983 |
Selby P, Buick RN, Tannock I. A critical appraisal of the 'human tumor stem-cell assay' New England Journal of Medicine. 308: 129-134. PMID 6336820 DOI: 10.1056/Nejm198301203080304 |
0.323 |
|
| 1982 |
Tannock I, Sutherland D, Osoba D. Failure of short-course multiple drug chemotherapy to benefit patients with recurrent or metastatic head and neck cancer. Cancer. 49: 1358-61. PMID 7059951 DOI: 10.1002/1097-0142(19820401)49:7<1358::Aid-Cncr2820490709>3.0.Co;2-K |
0.366 |
|
| 1982 |
Tannock I. Adriamycin: Effects on aerobic and hypoxic cells of the tumor and interaction with misonidazole International Journal of Radiation Oncology*Biology*Physics. 8: 813. DOI: 10.1016/0360-3016(82)90755-6 |
0.303 |
|
| 1981 |
Beex LVAM, Pieters GFFM, Smals AGH, Koenders AJM, Benraad TJ, Kloppenborg PWC, Jacquot C, Graterol R, Bariety J, Capron L, Fiessinger JN, Tannock I, Boyd N, Clark R, Feldman MI, et al. DES versus Tamoxifen in Advanced Breast Cancer The New England Journal of Medicine. 304: 1041-1043. PMID 7010171 DOI: 10.1056/Nejm198104233041714 |
0.307 |
|
| 1980 |
Tannock I. Cis-platinum and hormones in cancer of prostate. Urology. 16: 331-2. PMID 7191596 DOI: 10.1016/0090-4295(80)90060-6 |
0.328 |
|
| 1980 |
Tannock IF, Sutherland DJ. Chemotherapy for adenocystic carcinoma. Cancer. 46: 452-4. PMID 6249480 DOI: 10.1002/1097-0142(19800801)46:3<452::Aid-Cncr2820460305>3.0.Co;2-Z |
0.323 |
|
| 1979 |
Tannock IF. Chemotherapy for hypoxic tumor cells: Metronidazole and misonidazole in combination with conventional anti-cancer drugs Proceedings of the American Association For Cancer Research. |
0.313 |
|
| Show low-probability matches. |
